BRD product licensed for Mycoplasma bovis

Ceva Animal Health has extended the licence for Zeleris so it is now indicated for Mycoplasma bovis – one of the major pathogens responsible for bovine respiratory disease (BRD).

The new licence extension means Zeleris is licensed for the treatment of BRD associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and now M bovis. The latter causes several diseases in cattle, including respiratory disease in calves and arthritis, mastitis and pneumonia in older animals, generally in association with other pathogens.

Zeleris is an antibiotic and NSAID and features the a combination of florfenicol and meloxicam, in one convenient injection. It has a duration of action of up to three days.

Other pathogens

Harry Walby, ruminant veterinary advisor for Zeleris at Ceva Animal Health, said: “Mycoplasma bovis is notoriously difficult to contain and is very rarely isolated alone; it is frequently found alongside other pathogens including Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.

“In the absence of an effective commercial vaccine, antimicrobial therapy remains the main control measure and early administration of a NSAID/antibiotic combination treatment, such as Zeleris, can aid treatment response and reduce the fever that typically comes with BRD compared with using an antibiotic treatment alone.”

For further information, speak to a Ceva territory manager.

• This article was amended on 14 September 2023 as the headline in an earlier version incorrectly referred to a vaccine. We apologise for any confusion.